Skip to main content

Alzamend Neuro, Inc.

ALZN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001677077

In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.

Q4 2021 vs. Q3 2021

How the institutions holding Alzamend Neuro, Inc. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of ALZN: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders1720+3
Shares645.0K874.3K+229.3K (+35.6%)
Value$1.99M$1.66M−$325.0K (−16.3%)

New holders (13)

Institutions that held Alzamend Neuro, Inc. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to ALZN in Q4 2021
InstitutionSharesValue% of portfolio
Marshall Wace, LLP163,774$313.0K0.00%
Commonwealth Equity Services, LLC116,666$221.0K0.00%
Simplex Trading, LLC65,825$125.0K0.00%
Merit Financial Group, LLC50,000$95.0K0.01%
Engineers Gate Manager LP43,719$83.0K0.00%
Two Sigma Securities, LLC30,593$58.0K0.01%
Geode Capital Management, LLC29,791$56.0K0.00%
Virtu Financial LLC23,079$44.0K0.00%
Millennium Management LLC13,685$26.0K0.00%
XTX Topco Ltd11,134$21.0K0.01%
Principal Financial Group Inc10,400$20.0K0.00%
Insight Wealth Strategies, LLC10,000$19.0K0.00%
The PNC Financial Services Group, Inc.5,000$10.0K0.00%

Sold out (10)

Institutions that held Alzamend Neuro, Inc. at the end of Q3 2021 and filed for Q4 2021 without it.

Institutions that sold out of ALZN in Q4 2021
InstitutionShares, Q3 2021Value, Q3 2021
Two Sigma Investments, LP172,913$533.0K
Sassicaia Capital Advisers LLC93,762$289.0K
Qube Research & Technologies Ltd50,852$157.0K
Cubist Systematic Strategies, LLC46,669$144.0K
Citadel Advisors LLC45,225$139.0K
Schonfeld Strategic Advisors LLC31,600$97.0K
Tower Research Capital LLC (TRC)26,541$82.0K
Warberg Asset Management LLC14,000$43.0K
JPMorgan Chase & Co871$3.00K
Morgan Stanley326$1.00K